{"schema_version":"secwatch.filing_event.v1","accession":"0001299130-24-000164","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.504578+00:00","generated_at":"2026-05-31T11:38:33.618252+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PacBio Q2 revenue down 24% to $36M; GAAP net loss $173M includes $93M goodwill impairment","bullets":["Revenue of $36.0M vs $47.6M YoY; instrument revenue fell to $14.7M from $29.9M.","GAAP net loss $173.3M (-$0.64/sh); non-GAAP net loss $55.2M (-$0.20/sh).","Goodwill impairment charge of $93.2M; restructuring expenses of $18.0M included.","Cash $509.8M, down from $631.4M at Dec 31, 2023.","CEO expects revenue acceleration in H2; targeting >$75M annual expense reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001299130-24-000164","json":"https://secwatch.observer/filing/0001299130-24-000164.json","markdown":"https://secwatch.observer/filing/0001299130-24-000164.md","text":"https://secwatch.observer/filing/0001299130-24-000164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000164/0001299130-24-000164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000164/pacb-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:38:33.618252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}